Vaped Phenanthrene

University of Minnesota (UMN)

Status: Not yet enrolling

Conditions: Non-Smoker; Former Smoker

Treatments: Other: D10-phenanthrene

Study type: Interventional

Funder types: Other

Identifiers

NCT07134426

2022LS127

Details and patient eligibility

About

Some people who used to smoke cigarettes continue to be at higher risk of developing lung cancer, even years after quitting. This study will look to see if a specific chemical, phenanthrene, is broken down in the lungs of former smokers through more harmful pathways than never-smokers. If former smokers break down chemicals that enter their lungs through more harmful pathways this might be putting them at higher risk for developing lung cancer even though they quit smoking. This information may help find better ways to prevent or treat cancer in the future.

This study is under an IND, but the drug is not being studied; instead, it is being used as a marker for drug metabolism.

Enrollment: 100 estimated patients

Sex: All

Ages: 21+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• > 21 years of age
• In good physical & mental health
• In stable physical & mental health
• Have tried vaping
• Former daily cigarette smokers who quit 1-20 year ago
• Non-smokers who have not used tobacco or nicotine products

Exclusion criteria

• Has any respiratory disease (ex - asthma, COPD, etc...)
• Has/had high blood pressure
• Has/had liver disease
• Has/had cancer
• Has experience negative effects when vaped previously
• Pregnant or nursing

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

D10-phenanthrene

Other group

Description:

All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

Treatment:

Other: D10-phenanthrene